Little Green Pharma (ASX:LGP) Rises 16.67%: What Matters Beyond the Merger?

Sonal Goyal

12 November 2026 11:29 PM AEDT

Little Green Pharma (ASX:LGP) Rises 16.67%: What Matters Beyond the Merger?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key highlights

Little Green Pharma shares closed at 7 cents on 12 November 2026, up 16.67%, while the S&P/ASX 200 eased 0.07%.
The September 2026 quarter was the first full quarter of combined trading after the Merger with Cannatrek, generating unaudited Revenue of $26.0 million and Operating Cash Flow of $4.4 million.
Cash closed at $22.3 million, with borrowings of $5.2 million excluding leases.

Shares in Little Green Pharma Ltd (ASX:LGP) closed at 7 cents on 12 November 2026, up 16.67% on the session. S&P/ASX 200 closed at 9,146.80, down 0.07%. Little Green Pharma operates a cannabis-based pharmaceutical and consumer products group that merged with Cannatrek Ltd on 1 June 2026. Its latest update was its September 2026 quarterly activities report and Appendix 4C.

Post-merger quarter

The company reported unaudited revenue of $26.0 million and net operating cash inflow of $4.4 million for the quarter. Receipts from customers were $26.8 million, with product Manufacturing and operating costs of $15.0 million. Australia remained the principal market at 82% of sales, with Europe contributing 18% through the Danish operation. Flower made up 81% of group sales.

Synergies and expansion

Post-merger cost initiatives are targeting $3.0 million of savings, with some already actioned. An Investment program at the Danish Facility is focused on yield, efficiency and capacity. In the UK, the company has opened a London office, appointed a Country Manager and is advancing clinic and wholesale partnerships.

Sector context

The medicinal cannabis sector is subject to regulatory oversight in each jurisdiction, and sales mix and pricing can shift quickly as product categories change. The broader market was little changed on 12 November.

Risks and limitations

The company said it has previously disclosed a regulatory investigation by the Therapeutic Goods Administration and anticipates that any penalty could be material. The quarter's figures are unaudited and the accounting treatment of the merger affects comparisons. Borrowings are $5.2 million.

What to watch ahead

Investors will look for delivery of the $3.0 million synergy target, progress on the TGA investigation and the outcome of UK clinic and wholesale partnerships.

FAQs

Q: What was the closing price of Little Green Pharma on 12 November 2026?

A: Shares closed at 7 cents, up 16.67% on the session.

Q: How much cash did the company hold?

A: Cash and cash equivalents were $22.3 million at 30 September 2026.

Q: What is the synergy target?

A: Initiatives are targeting $3.0 million of savings, with some already actioned.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.